SAREPTA THERAPEUTICS INC's ticker is SRPT and the CUSIP is 803607100. A total of 353 filers reported holding SAREPTA THERAPEUTICS INC in Q3 2018. The put-call ratio across all filers is 0.81 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $16,001,040 | +139622.7% | 132,000 | +131900.0% | 0.18% | – |
Q2 2023 | $11,452 | -99.9% | 100 | -99.9% | 0.00% | -100.0% |
Q4 2022 | $16,314,122 | +17.2% | 125,900 | 0.0% | 0.17% | +12.7% |
Q3 2022 | $13,916,000 | +58.9% | 125,900 | +7.8% | 0.15% | +70.5% |
Q2 2022 | $8,755,000 | -48.3% | 116,800 | -46.1% | 0.09% | -46.7% |
Q1 2022 | $16,936,000 | -23.6% | 216,800 | -11.9% | 0.16% | -19.9% |
Q4 2021 | $22,170,000 | +6.4% | 246,200 | +9.2% | 0.21% | +14.4% |
Q3 2021 | $20,844,000 | +137.9% | 225,400 | +99.9% | 0.18% | +168.7% |
Q2 2021 | $8,762,000 | +2042.3% | 112,729 | +1949.6% | 0.07% | +2133.3% |
Q1 2021 | $409,000 | -89.5% | 5,500 | -76.0% | 0.00% | -89.7% |
Q4 2020 | $3,903,000 | +69.5% | 22,900 | +39.6% | 0.03% | +45.0% |
Q3 2020 | $2,303,000 | -4.3% | 16,400 | +9.3% | 0.02% | -16.7% |
Q2 2020 | $2,406,000 | +64.0% | 15,011 | +0.1% | 0.02% | +14.3% |
Q1 2020 | $1,467,000 | -59.7% | 15,000 | -46.8% | 0.02% | -50.0% |
Q4 2019 | $3,638,000 | +48.2% | 28,200 | -13.5% | 0.04% | +35.5% |
Q3 2019 | $2,455,000 | -34.3% | 32,600 | +32.6% | 0.03% | -36.7% |
Q2 2019 | $3,734,000 | +187.7% | 24,588 | +125.6% | 0.05% | +172.2% |
Q1 2019 | $1,298,000 | +284.0% | 10,899 | +251.6% | 0.02% | +350.0% |
Q4 2018 | $338,000 | -32.4% | 3,100 | 0.0% | 0.00% | -33.3% |
Q3 2018 | $500,000 | +22.2% | 3,100 | 0.0% | 0.01% | +20.0% |
Q2 2018 | $409,000 | -26.4% | 3,100 | -69.0% | 0.01% | -16.7% |
Q4 2017 | $556,000 | -7.0% | 10,000 | -24.2% | 0.01% | -14.3% |
Q3 2017 | $598,000 | -50.8% | 13,200 | -67.9% | 0.01% | -63.2% |
Q1 2017 | $1,216,000 | +1069.2% | 41,100 | +981.6% | 0.02% | +1800.0% |
Q4 2016 | $104,000 | -56.5% | 3,800 | -2.6% | 0.00% | -75.0% |
Q3 2016 | $239,000 | -77.7% | 3,900 | -88.5% | 0.00% | -82.6% |
Q1 2014 | $1,073,000 | +203.1% | 33,800 | +240.7% | 0.02% | +228.6% |
Q4 2013 | $354,000 | +6980.0% | 9,921 | +47142.9% | 0.01% | – |
Q3 2013 | $5,000 | – | 21 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Ikarian Capital, LLC | 399,400 | $35,962,000 | 5.36% |
Avoro Capital Advisors LLC | 3,125,000 | $281,406,000 | 4.79% |
Varenne Capital Partners | 324,661 | $29,236,000 | 4.34% |
Evolutionary Tree Capital Management, LLC | 96,695 | $8,707,000 | 4.18% |
Ally Bridge Group (NY) LLC | 120,000 | $10,806,000 | 3.78% |
Casdin Capital, LLC | 1,350,000 | $121,568,000 | 3.43% |
Ghost Tree Capital, LLC | 100,000 | $9,005,000 | 3.23% |
GREAT POINT PARTNERS LLC | 145,405 | $13,094,000 | 2.91% |
Camber Capital Management LP | 825,000 | $74,291,000 | 2.55% |
Alpha DNA Investment Management LLC | 17,522 | $1,577,000 | 1.00% |